ID   Hep-G2-THRA MUT p.I116N;A225T;M388I
AC   CVCL_C3GA
SY   HepG2 RCCC-THRA mutant 6; rc6-TRalpha1
DR   cancercelllines; CVCL_C3GA
DR   GEO; GSM721672
DR   GEO; GSM721673
DR   GEO; GSM721674
DR   GEO; GSM721675
DR   GEO; GSM721676
DR   GEO; GSM721677
DR   Wikidata; Q114311594
RX   PubMed=21622534;
CC   Population: Caucasian.
CC   Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Leu (c.182A>T); ClinVar=VCV000375874; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line).
CC   Transfected with: HGNC; 11796; THRA (with p.Ile116Asn; p.Ala225Thr and p.Met388Ile).
CC   Transfected with: UniProtKB; P00552; Transposon Tn5 neo.
CC   Omics: Transcriptome analysis by microarray.
CC   Derived from site: In situ; Liver; UBERON=UBERON_0002107.
DI   NCIt; C3728; Hepatoblastoma
DI   ORDO; Orphanet_449; Hepatoblastoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_0027 ! Hep-G2
SX   Male
AG   15Y
CA   Cancer cell line
DT   Created: 22-09-22; Last updated: 05-10-23; Version: 5
//
RX   PubMed=21622534; DOI=10.1210/me.2010-0420;
RA   Rosen M.D., Chan I.H., Privalsky M.L.;
RT   "Mutant thyroid hormone receptors (TRs) isolated from distinct cancer
RT   types display distinct target gene specificities: a unique regulatory
RT   repertoire associated with two renal clear cell carcinomas.";
RL   Mol. Endocrinol. 25:1311-1325(2011).
//